Previous 10 | Next 10 |
OptimizeRx (NASDAQ:OPRX) is acquiring specialty drug prescription initiation platform EvinceMed and related assets. The company said EvinceMed delivers end-to-end automation for specialty pharmaceutical transactions. The acquisition includes the full Market Access Management Platform supporti...
ROCHESTER, Mich., March 15, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced a definitive agreement to acquire the Evin...
ROCHESTER, Mich., March 07, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced that its senior vice president of corporate finan...
Image source: The Motley Fool. OptimizeRx Corporation (NASDAQ: OPRX) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: OptimizeRx Corporation (OPRX) Q4 2021 Earnings Call Transcript
OptimizeRx Corporation. (OPRX) Q4 2021 Earnings Conference Call February 24, 2022, 04:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer Stephen Silvestro - Chief Commercial Officer Andrew D’Silva - Senior Vice President of Corpo...
OptimizeRx press release (NASDAQ:OPRX): Q4 Non-GAAP EPS of $0.22 beats by $0.18. Revenue of $20.3M (+23.6% Y/Y) beats by $5.5M. For further details see: OptimizeRx Non-GAAP EPS of $0.22 beats by $0.18, revenue of $20.3M beats by $5.5M
Fourth quarter revenue Up 24% to $20.3 million, gross profit margin of 61% Introduction of key performance indicators (KPIs) representing “land and expand” strategy with key customer accounts Cash flow positive from operations of $0.7 million in 2021 ROCHES...
ROCHESTER, Mich., Feb. 22, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the launch of a large-scale therapy initiation pr...
OptimizeRx (NASDAQ:OPRX) announces preliminary Q4 revenue of $20.3M, resulting in a Y/Y growth of 42%. Improved gross margins and continued cost management are expected to result in a GAAP net income of $0.6M for Q4 as well as a record quarterly adjusted EBITDA of $4M. 2022 Guidance: FY ...
ROCHESTER, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced preliminary unaudited financial and operatio...
News, Short Squeeze, Breakout and More Instantly...
OptimizeRx Corporation Company Name:
OPRX Stock Symbol:
NASDAQ Market:
OptimizeRx Corporation Website:
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a confere...
WALTHAM, Mass., July 23, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced its conti...
WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced the resul...